FilingReader Intelligence
Joincare's psoriasis drug meets phase III trial endpoint
July 21, 2025 at 11:10 AM UTC•By FilingReader AI
Joincare Pharmaceutical Group's antibody injection LZM012 met its primary endpoint in a phase III trial for moderate to severe plaque psoriasis.
At week 12, LZM012 showed a 49.5% PASI 100 response rate versus 40.2% for the control group, demonstrating superiority. The company is applying for marketing approval.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:600380•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Joincare Pharmaceutical Group Industry publishes news
Free account required • Unsubscribe anytime